Literature DB >> 17316891

Chemotherapy induced reversible posterior leukoencephalopathy syndrome.

Roisin M Connolly1, Colin P Doherty, Peter Beddy, Ken O'Byrne.   

Abstract

The reversible posterior leukoencephalopathy syndrome (RPLES) is a condition characterised by reversible neurological and radiological findings that has been associated with use of immunosuppressive, chemotherapeutic and more recently novel targeted therapies. We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy. The clinical, radiological and EEG findings during and post event are presented and are in keeping with a diagnosis of RPLES. Early recognition of this rare syndrome, supportive management and withdrawal of the offending agent appear to result in a reversal of the manifestations described.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17316891     DOI: 10.1016/j.lungcan.2007.01.012

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  15 in total

Review 1.  Reversible posterior leukoencephalopathy syndrome in cancer.

Authors:  Christopher Vaughn; Louann Zhang; David Schiff
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

2.  Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study.

Authors:  Carlos Kamiya-Matsuoka; Asif M Paker; Linda Chi; Ayda Youssef; Sudhakar Tummala; Monica E Loghin
Journal:  J Neurooncol       Date:  2016-02-22       Impact factor: 4.130

3.  Primary brain tumors and posterior reversible encephalopathy syndrome.

Authors:  Carlos Kamiya-Matsuoka; David Cachia; Adriana Olar; Terri S Armstrong; Mark R Gilbert
Journal:  Neurooncol Pract       Date:  2014-09-14

4.  [Cerebral vasculitis associated with gemcitabine].

Authors:  P Schmorl; A Heer-Sonderhoff; R Vosshenrich; S Conrad
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

5.  Posterior reversible encephalopathy syndrome (PRES) complicating the 'legal high' mephedrone.

Authors:  Taha Adam Omer; Colin Doherty
Journal:  BMJ Case Rep       Date:  2011-08-29

6.  Reversible posterior leukoencephalopathy syndrome associated with concurrent bevacizumab, gemcitabine, and oxaliplatin for cholangiocarcinoma.

Authors:  Yongen Chang; Gilbert Mbeo; Susan J Littman
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 7.  Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature.

Authors:  Joan How; Margaret Blattner; Susan Fowler; Andrea Wang-Gillam; Suzanne E Schindler
Journal:  Neurologist       Date:  2016-11       Impact factor: 1.398

8.  Chemotherapy-related posterior reversible leukoencephalopathy syndrome.

Authors:  Archit Bhatt; Muhammad U Farooq; Arshad Majid; Mounzer Kassab
Journal:  Nat Clin Pract Neurol       Date:  2009-03

Review 9.  Posterior reversible encephalopathy syndrome: a neurologic phenomenon in cancer patients.

Authors:  Eileen M Le; Monica E Loghin
Journal:  Curr Oncol Rep       Date:  2014-05       Impact factor: 5.075

Review 10.  Imaging 'the lost tribe': a review of adolescent cancer imaging. Part 2: imaging of complications of cancer treatment.

Authors:  I Zerizer; P D Humphries
Journal:  Cancer Imaging       Date:  2009-11-06       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.